SK
SKIN.US SkinHealth Systems Inc.
- Market cap
- USD 90.4M
- P/E
- -
- P/B
- 1.76x
- ROE
- -24.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SKIN.US undervalued?
Graham numberThe Graham number of SkinHealth Systems Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SkinHealth Systems Inc. fundamental analysis
No fundamental analysis for SkinHealth Systems Inc. yet.
SkinHealth Systems Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SkinHealth Systems Inc.
SkinHealth Systems Inc., a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America. The company's flagship product is HydraFacial, which enhances the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. It also offers Syndeo devices, which are delivery systems that are designed to connect providers to the c…
Full company profileSkinHealth Systems Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SkinHealth Systems Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 112M | 167M | 119M | 260M | 366M | 398M | 334M | 301M | 275M |
| Gross Profit | 73.0M | 107M | 67.2M | 179M | 249M | 155M | 182M | 196M | 188M |
| Operating Income | 10.1M | 13.5M | -17.2M | -39.9M | -25.8M | -131M | -67.8M | -20.8M | 9.00M |
| EBITDA | 21.6M | 28.1M | -2.68M | -351M | 81.6M | -53.6M | 14.5M | 38.7M | 35.2M |
| Net Income | -317K | -1.64M | -29.2M | -379M | 44.2M | -100M | -29.1M | -9.52M | -13.5M |
| EPS | -0.05 | -1.02 | -17 | -3.71 | 5.96 | -15 | -4.08 | -1.40 | -2.08 |
| Balance Sheet | |||||||||
| Total Assets | - | 226M | 223M | 1.22B | 1.00B | 929M | 686M | 500M | 389M |
| Total Liabilities | - | 228M | 253M | 917M | 836M | 870M | 634M | 439M | 333M |
| Shareholders' Equity | - | -1.21M | -30.0M | 302M | 167M | 59.4M | 51.8M | 61.1M | 55.8M |
| Cash & Short-term Investments | - | 7.31M | 9.49M | 902M | 568M | 523M | 370M | 233M | 112M |
| Total Debt | - | 190M | 217M | 734M | 752M | 752M | 568M | 379M | 264M |
| Cash Flow | |||||||||
| Operating Cash Flow | -895K | 1.73M | -12.4M | -28.4M | -107M | 21.8M | 16.1M | 37.5M | 11.2M |
| Capital Expenditure | 7.89M | 10.4M | 3.82M | 15.6M | 17.4M | 13.0M | 6.79M | 5.16M | 5.22M |
| Free Cash Flow | -8.78M | -8.69M | -16.3M | -44.0M | -124M | 8.70M | 9.34M | 32.3M | 5.98M |
| Ratios | |||||||||
| ROE | - | - | - | -125.3% | 26.5% | -168.6% | -56.2% | -15.6% | -24.3% |
| ROA | - | -0.7% | -13.1% | -31.1% | 4.4% | -10.8% | -4.2% | -1.9% | -3.5% |
| Net Profit Margin | -0.3% | -1.0% | -24.5% | -145.6% | 12.1% | -25.2% | -8.7% | -3.2% | -4.9% |
| Debt to Equity | - | - | - | 2.43x | 4.50x | 12.67x | 10.97x | 6.20x | 4.74x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
SkinHealth Systems Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 323K | 0.19 | - |
| 2019 | - | - | - |
| 2018 | USD 98.7M | 16 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Oct 14, 2026.
Who owns SkinHealth Systems Inc.
- Insiders 12.82%
- Institutions 68.90%
- Public & others 18.28%
- Shares outstanding 6.52M
- Free float 3.17M
Top funds holding SKIN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.48M | 1.91% | 0.00% | Sep 2026 |
| Silver Point Spe Lend A-1 Debt-CLO | 913K | 0.70% | 0.00% | Jun 2026 |
| Fidelity Extended Market Index | 422K | 0.32% | -0.38% | Sep 2026 |
| Fidelity Total Market Index | 146K | 0.11% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 122K | 0.09% | 0.00% | Sep 2026 |
| AQR Delphi L/S Eq IAU1F | 64.1K | 0.05% | -50.00% | Mar 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 50.4K | 0.04% | 0.00% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 37.8K | 0.03% | +837.83% | Jun 2026 |
| Vanguard Balanced Index Inv | 37.2K | 0.03% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 33.7K | 0.03% | 0.00% | Sep 2026 |
| Russell Inv US Small Cap Equity Y | 22.8K | 0.02% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 14.4K | 0.01% | -83.59% | Aug 2026 |
| JNL/DFA US Small Cap A | 14.2K | 0.01% | 0.00% | Sep 2026 |
| Dimensional Global Small Coms USD Acc | 8.93K | 0.01% | 0.00% | Sep 2026 |
| Dimensional US Sm Company EUR Acc | 8.89K | 0.01% | -0.30% | Sep 2026 |
| Dimensional Gl Cor Eq LC ESG Sc USD A | 7.27K | 0.01% | -0.40% | Sep 2026 |
Top institutions holding SKIN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Capricorn Fund Managers Ltd | 22.3M | 17.10% | +14.80% | Jun 2026 |
| FMR Inc | 10.2M | 7.83% | -40.63% | Jun 2026 |
| BlackRock Inc | 8.52M | 6.54% | +15.75% | Jun 2026 |
| Millennium Management LLC | 7.54M | 5.78% | +31.82% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.50M | 2.68% | +1.61% | Jun 2026 |
| Woodline Partners LP | 2.33M | 1.79% | -59.14% | Jun 2026 |
| Silver Point Capital LP | 1.59M | 1.22% | 0.00% | Jun 2026 |
| D. E. Shaw & Co LP | 1.43M | 1.10% | -24.55% | Jun 2026 |
| Geode Capital Management, LLC | 960K | 0.74% | -57.16% | Jun 2026 |
| UBS Group AG | 839K | 0.64% | +249.23% | Jun 2026 |
| Squarepoint Ops LLC | 674K | 0.52% | +125.05% | Jun 2026 |
| Glendon Capital Management LP | 637K | 0.49% | 0.00% | Jun 2026 |
| Prescott Group Capital Management LLC | 578K | 0.44% | -9.61% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 497K | 0.38% | -15.26% | Jun 2026 |
| AQR Capital Management LLC | 484K | 0.37% | -3.23% | Jun 2026 |
| Charles Schwab Investment Management Inc | 410K | 0.32% | -43.47% | Jun 2026 |
| Grimes & Company, Inc. | 407K | 0.31% | 0.00% | Jun 2026 |
| State Street Corp | 387K | 0.30% | -79.45% | Jun 2026 |
| Renaissance Technologies Corp | 365K | 0.28% | +28.51% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 327K | 0.25% | -4.71% | Jun 2026 |
SkinHealth Systems Inc. company profile
- Company name
- SkinHealth Systems Inc.
- Ticker
- SKIN.US
- Exchange
- USA Stocks
- Listed since
- Nov 24, 2020
- Sector
- Consumer Defensive
- Industry
- Personal Care Products
- Employees
- 613
- Fiscal year end
- December
- Address
- 3600 E. Burnett Street, Long Beach, CA, United States, 90815
- Phone
- 800 603 4996
- Website
- skinhealthsystems.com
About SkinHealth Systems Inc.
SkinHealth Systems Inc., a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America. The company's flagship product is HydraFacial, which enhances the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. It also offers Syndeo devices, which are delivery systems that are designed to connect providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling and nanoneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive peptide solutions and take home sprays for treating scalp health. In addition, it operates the MyBeautyHealth mobile application for consumers to earn loyalty points and unlock savings, log skin concerns and receive personalized treatment plans, and find and connect with Hydrafacial providers, as well as offers boosters. The company was formerly known as The Beauty Health Company and changed its name to SkinHealth Systems Inc. in April 2026. The company was founded in 1997 and is headquartered in Long Beach, California.
SkinHealth Systems Inc. management
6- Mr. Pedro MalhaCEO, President & Director · born 1972
- Mr. Michael P. MonahanChief Financial & Operating Officer · born 1972
- Mr. Paul Bokota J.D.Chief Legal, People & Compliance Officer
- Ms. Whitney CypesChief Marketing, Clinical & Innovation Officer
- Ms. Tanja WirtzSenior Vice President of International
- Ms. Kelly PenningtonSenior Vice President of Americas